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ABSTRACT 
 
Transfemoral approach stands as the reference access-route for transcatheter aortic valve implantation 
(TAVI). Nonetheless, alternatives approaches are still needed in a significant proportion of patients. 
This study aimed at comparing outcomes between transthoracic-approach (transapical or transaortic) 
and transarterial-approach (transcarotid or sub-clavian) TAVI. Data from 191 consecutive patients 
who underwent surgical-approach TAVI from May 2009 to September 2017 were analyzed. Patients 
were allocated in two groups according to the approach. The primary endpoint was the 30-day 
composite of death of any cause, need for open surgery, tamponade, stroke, major or life-threatening 
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bleeding, stage 2 or 3 acute kidney injury, coronary obstruction, or major vascular complications. 
During the study period, 104 patients underwent transthoracic TAVI (transapical: 60.6%, transaortic: 
39.4%) whereas 87 patients underwent transarterial TAVI (sub-clavian: 83.9%, transcarotid: 16.1%). 
Logistic EuroSCORE I tended to be higher among transthoracic-TAVI recipients. In-hospital and 30-
day composite endpoint rates were 25.0% and 11.5% (p = 0.025), and 26.0% and 14.9% (p=0.075) for 
the transthoracic and transarterial cohorts, respectively. Propensity score-adjusted logistic regression 
demonstrated no significant detrimental association between the 30-day composite endpoint and 
transthoracic access (OR: 2.12 95% CI: 0.70-6.42; p=0.18). Transarterial TAVI was associated with a 
shorter length of stay (median: 6 vs. 7 days, p<0.001). TAVI approach was not an independent 
predictor of mid-term mortality. In conclusion, non-transfemoral transarterial-approach TAVI is safe, 
feasible, and associated with comparable rates of major perioperative complications, and mid-term 
mortality compared with transthoracic-approach TAVI. 
 
KEYWORDS: Aortic stenosis, Transcatheter aortic valve implantation, Surgical approaches 
 
Since the publication of the randomized Placement of Aortic Transcatheter Valves 
(PARTNER) trials
1–3
, transcatheter aortic valve implantation (TAVI) is recognized as an efficient 
therapy for treatment of severe aortic stenosis in inoperable, high and intermediate-risk patients. 
Transfemoral approach, as the less invasive and safest access, stands as the reference access route for 
TAVI. Although non-transfemoral approaches are decreasing with the miniaturization of delivery 
systems, in a recent national registry 17.2% of patients were still treated by non-transfemoral 
accesses
4
. Alternative approaches requiring a surgical contribution include transaortic, transapical, 
sub-clavian, and, lately, transcarotid access. Transapical access is well-described
5
 and provides 
acceptable results. The transaortic approach requires to expose the ascending aorta using a mini-
sternotomy or a right thoracotomy, and is associated with similar outcomes as transapical access
6,7
. 
Considering their invasiveness, the use of these transthoracic approaches is decreasing. Sub-clavian 
access is a safe method, showing comparable results to transfemoral approach
8
, however with the 
same limitations regarding vessel  anatomy, and  being unsuited for patients with thoracic artery 
grafts. Transcarotid access tends to represent a growing proportion of alternative accesses, despite 
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ongoing questions regarding the risk of stroke
9,10
. Given the paucity of direct comparisons of 
alternative accesses in the current literature, the aim of this study was to compare short and mid-term 
outcomes between patients undergoing transthoracic (transapical or transaortic) TAVI and transarterial 
(transcarotid or sub-clavian) TAVI.  
 
 
METHODS 
All patients who underwent a non-transfemoral approach TAVI at our institution (Rennes 
University Hospital, Rennes, France) from May 2009 to September 2017 were included. Details 
regarding the pre-procedural evaluation and follow-up modalities were previously published
11
. Details 
regarding the access selection process by the Heart Team are provided in the supplementary 
appendix. All patients gave written informed consent for the procedures and anonymous collection of 
their data, which were prospectively gathered in an electronic database. The institutional review board 
waived specific consent for this study due to its retrospective and observational nature. 
Chronic lung disease was defined as a restrictive lung disease or a chronic obstructive 
pulmonary disease. Cerebrovascular disease was defined as a previous carotid surgery or a stenosis ≥ 
50% of carotid or vertebral arteries. Peripheral artery disease included artery stenosis ≥ 50%, 
claudication and previous vascular surgery.  Surgical risk was estimated with the logistic EuroScore I, 
the logistic EuroScore II and the Society of Thoracic Surgeons Predicted Risk Of Mortality score. 
Valve Academic Research Consortium 2 (VARC-2) standards were used to define hostile chest, 
severe liver disease and all study endpoints
12
.  
The primary endpoint was the 30-day rate of major perioperative complications defined as the 
composite of death of any cause, need for open surgery, tamponade, stroke, major or life-threatening 
bleeding, stage 2 or 3 acute kidney injury, coronary obstruction, or major vascular complications. 
Secondary endpoints were in-hospital and 30-day rates of the components of the primary endpoint and 
survival at follow-up. 
Patients were included, according to the access site used, in the transthoracic (transapical or 
transaortic access) or transarterial (sub-clavian or transcarotid access) groups. Continuous variable are 
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presented as mean ± standard deviation or median (interquartile range) depending on their distribution, 
which was assessed using the Kolmogorov-Smirnov test, and were compared using t tests or the 
Mann-Whitney U test as appropriate. Categorical variables are summarized as numbers (percentages), 
and were compared using chi-square tests or the Fisher exact test. Survival rates were summarized 
using Kaplan-Meier estimates, and log-rank tests were used to compare groups. To evaluate the impact 
of access-site on the rate of the primary endpoint while adjusting for baseline differences between 
groups, propensity score-adjusted multivariable logistic regression was performed. Results are 
expressed as adjusted odds ratio (OR) with its 95% confidence interval (CI). The propensity score was 
calculated as the probability of undergoing transthoracic access using a non-parsimonious logistic 
regression model. Details regarding variables included in the propensity score can be found in the 
supplementary appendix. The propensity score model had adequate calibration (Hosmer-Lemeshow 
goodness-of-fit p=0.46) and discrimination (c-statistic=0.93, 95% CI: 0.89-0.97). Predictors of all-
cause mortality were analyzed using univariable and multivariable proportional hazard models 
(cumulative outcomes). The proportional hazard assumption was tested by plotting log-minus-log 
survival. Variables with p-values <0.1 in univariable analysis and the access-route were included in 
the multivariable analysis. Statistical analysis was performed with the use of Statistical Package for 
Social Sciences version 22 (SPSS, Chicago, IL, USA). All tests were 2-sided at the 0.05 significance 
level. 
  
RESULTS 
During the study period, 191 patients (female sex: 39%) had a non-transfemoral approach 
TAVI, among which 87 patients (mean-age: 79.3±6.7 years) underwent a transarterial approach and 
104 patients (mean-age: 78.0±9.9 years) a transthoracic approach. Sub-clavian access was performed 
in 73 patients (38.2%), transcarotid in 14 patients (7.3%), transaortic in 41 patients (21.5%), and 
transapical in 63 patients (33.0%). Supplemental Figures 1 and 2 show the annual number of each 
alternative access, and the annual proportion of all TAVI represented by each of these accesses. 
Baseline characteristics of the study population according to the approach are summarized in Table 1. 
Coronary artery disease was significantly more frequent in the transthoracic group than in the 
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transarterial group (68.3% vs. 48.4%; p=0.008). Patients of the transthoracic group harbored a higher 
burden of cerebrovascular disease (18.4% vs. 3.4%; p=0.001) and hostile chest (5.8% vs. 0.0%; 
p=0.03). Prevalence of peripheral artery disease was similar in both groups. Mean Logistic EuroScore 
I tended to be higher in patients treated with the transthoracic approach (14.9% vs. 12.0%; p=0.053). 
Echocardiographic parameters were similar between groups. 
Procedural characteristics are described in Table 2. General anaesthesia was used in all transthoracic 
procedures, and in 90.8% of the transarterial ones (p = 0.002). Balloon-expendable valves were much 
more frequently implanted in the transthoracic group (96.2% vs. 26.4%; p<0.001). Device success was 
achieved in 95.2% of transthoracic TAVI recipients compared with 85.1% of their transarterial 
counterparts (p=0.024). Major intra-procedural complications were comparable between groups (Table 
2). 
In-hospital and 30-day outcomes of the 2 groups are depicted in Table 3. Supplemental 
Tables 1 and 2 present a comparison of subclavian vs. transcarotid approaches, and transaortic vs. 
transapical approaches, respectively. In univariate analysis, the in-hospital composite endpoint rate 
was significantly higher in the transthoracic access cohort (25.0% vs. 11.5%; p=0.025), yet this 
difference did not persist at 30-day (26.0 vs. 14.9%, p=0.075). Propensity score-adjusted logistic 
regression confirmed the absence of a significant association between the 30-day composite endpoint 
and transthoracic access (OR: 2.12, 95% CI: 0.70-6.42; p=0.18). Albeit numerically higher in the 
transthoracic cohort, there was no significant difference between groups for in-hospital (4.6% vs. 
7.7%; p=0.55) and 30-days (4.6% vs. 8.7%; p=0.39) mortality. Also numerically higher in the 
transthoracic group, incidences of most major periprocedural complications were statistically 
comparable between groups. One contralateral transient ischemic attack occurred 24h post-procedure 
in a patient who underwent left transcarotid TAVI under general anesthesia without balloon 
predilation. New-onset atrial fibrillation and acute kidney injury stage 2 or 3 were more prevalent in 
the transthoracic cohort. In the transthoracic access group, consistently with the lower use of self-
expendable valves, TAVI resulted in a lower rate of permanent pacemaker implantation than in the 
transarterial cohort. Length of hospitalization was higher (7.0 days vs. 6.0 days; p<0.001) and patients 
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were less often discharged at home (42.0% vs. 68.7%; p=0.002) in the transthoracic cohort. 
Echocardiographic findings at discharge are presented in Table 3.  
Median follow-up was 395 days (interquartile range [IQR]: 320-974) and was significantly 
longer in the transthoracic cohort (676 days, IQR: 367-1182, vs. 367 days, IQR: 204-427; p<0.001). 
The 1-year Kaplan-Meier survival curves are shown in Figure 1. At 1 year, overall survival was 
similar in both groups (89.6%; 95% CI: 80.1-94.7 and 84.5%; 95% CI: 75.9-90.2 with the transarterial 
and transthoracic approach, respectively; p=0.30). Figure 2 summarizes the multivariable predictors 
of all-cause mortality at follow-up. Atrial fibrillation (HR: 2.52; 95% CI: 1.33-4.78; p=0.005), STS-
PROM score (HR: 1.18; 95% CI: 1.01-1.39; p=0.04) and periprocedural stroke (HR: 5.85; 95% CI: 
1.51-22.63; p=0.011) were found as independent predictors of overall mortality. Transthoracic access-
route was not independently associated with mortality at follow-up (HR: 1.16; 95% CI: 0.55-2.45; 
p=0.70) 
 
DISCUSSION 
The main findings of this study are the following: despite a numerically lower incidence 
among transarterial TAVI patients, transthoracic approaches were not significantly associated with an 
increased rate of 30-days major perioperative adverse events or decreased mid-term survival (Figure 
3). However, a shorter length of stay and a higher likelihood of being discharge at home were 
observed among transarterial TAVI recipients. 
At the inception of the TAVI era, when a transfemoral approach was not feasible, a 
“transapical-first” policy was usually applied. Currently, strategies tend to evolve, with a priority for 
less invasive approaches. In a recent analysis of temporal trends in French registries
4
, transapical 
TAVI drastically decreased over time (from 27.9% in 2010 to 4.7% in 2015 among patients receiving 
a balloon-expandable valve). This evolution can be explained by an increase of transfemoral TAVI 
(73.4% vs. 82.8%) and the expansion of alternative access-sites of more recent emergence such as the 
direct aortic, and, particularly, transcarotid routes (5.5% and 3.4% of 12804 patients included in the 
FRANCE TAVI registry, respectively). Comparable findings were previously reported in the UK 
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registry
13
. However, the transcarotid approach being the latest implemented in routine practice, the 
above-mentioned trend will likely accentuate regarding this specific access.  
Transapical and transaortic TAVI are associated with similar rates of complications and 
comparable outcomes
6,7
. Our results regarding the in-hospital and 30-days morbidity and mortality of 
transthoracic TAVI are consistent with these recent studies. On the contrary to transthoracic TAVI, 
some groups reported favourable outcomes, sometimes comparable with the transfemoral approach, 
with the use of transcarotid and subclavian TAVI
8,14,15
. Therefore, these alternative transarterial 
accesses could conceivably be superior to transthoracic ones, and should represent the first option 
when transfemoral TAVI cannot be performed. However, the paucity of direct comparisons between 
non-transfemoral approaches supporting this assumption is highlighted by the observation that 
transthoracic access still represents the majority of alternative access TAVI in some regions, such as 
the US
16
. The present study adds to a small number of publications, which investigated the potential 
benefits of practicing a transarterial instead of a transthoracic approach
9,17,18,19
. As in the present study, 
a 3 Italian centers retrospective study also reported a non-significant trend to increased peri-procedural 
events, which did not impact mid-term survival, with the use of transapical versus subclavian TAVI
18
. 
Within the larger UK registry, Fröhlich et al demonstrated a significantly higher 2-year mortality 
following transapical or transaortic access than after transfemoral or subclavian TAVI
17
. Recently, 
using propensity score-matching, Chamandi et al published the largest comparative analysis 
specifically involving alternative access
19
. Ninety-four transcarotid TAVI recipients were matched 
with 163 transthoracic TAVI patients. Transcarotid access was associated with reduced 30-days rates 
of new-onset atrial fibrillation, major or life-threatening bleeding, stage 2 or 3 acute kidney injury, and 
a shorter length of stay. Mortality, stroke and device success were comparable between groups while 
early safety favored transcarotid access. The present study reports largely consistent findings. 
 Stroke was numerically higher in the transthoracic cohort, without significant difference 
between groups (3.8% vs. 1.1%; p = 0.38), which may be related to the small sample size. Beyond 
their heavier atherosclerotic burden, new-onset atrial fibrillation, a condition considerably more 
prevalent after transthoracic TAVR and associated with a higher risk of 30-days cerebrovascular 
events
20
, may significantly contribute to an increased risk among recipients of this approach. This 
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finding may be of paramount importance, as consistently with our results, periprocedural stroke was 
an independent predictor of mortality in previous studies
21
. Moreover, although local anesthesia was 
not consistently associated with better outcomes
22
, a higher rate of periprocedural stroke has been 
suggested with general anesthesia following transcarotid TAVI
23
. Only 50% of transcarotid approach 
patients were treated under local anesthesia with sedation in the present study. Whether a broader use 
of local anesthesia and sedation with growing experience with this approach improves neurological 
outcomes should be the focus of future studies.   
On the contrary, permanent pacemaker implantation was more frequent in the transarterial-
access cohort. As reported in previous studies
24
, this finding is related to the higher implantation rate 
of self-expandable valves in the transarterial group. With the expansion of TAVI to lower-surgical risk 
and younger patients, this result raises the major issue of potentially negative effects of long-term 
pacing, even if the impact of permanent pacemaker implantation after TAVI remains debated
24,25
. 
However, during the early experience of TAVI, subclavian approach was almost exclusively 
performed with self-expandable valve. Yet, with growing experience, balloon-expandable valves are 
increasingly implanted through this access, which should mitigate its detrimental association with 
post-procedural pacemaker implantation. 
Several limitations need to be acknowledged. First, there were significant differences in 
baseline characteristics between the two groups, which we attempted to adjust for by propensity score-
adjustment. Nonetheless, no statistical method can provide the degree of bias reduction obtained with 
randomization. Therefore, residual confounding, related to the higher burden of comorbidities 
observed in the transthoracic group, cannot be ruled out. Second, this is a retrospective analysis, based 
on a single center population with a limited number of patients in both cohorts, which implies a 
significant risk of type II error.  Furthermore, because of the relatively recent development of this 
strategy in our center, the transcarotid approach was less represented than the subclavian access-route 
in the transarterial cohort. Considering the well-known learning-curve effect with other approaches 
26,27
, we can hypothesized that our lower experience regarding transcarotid procedures in comparison 
with others approaches potentially influenced our results. Conversely, transcarotid TAVI was likely 
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performed using more advanced valve technologies among patients with a lower surgical risk, which 
may have balanced our limited experience.  
 
CONCLUSION 
Non-transfemoral transarterial-approach TAVI is safe, feasible, and associated with 
comparable rates of major perioperative complications, and mid-term mortality compared with 
transthoracic-approach TAVI. Nonetheless, transarterial access may be associated with lower rates of 
new-onset atrial fibrillation, acute kidney injury, and shorter hospitalization.  
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Figure 1 - Rates of all-cause mortality 
Kaplan-Meier curves at 1-year follow-up for overall mortality according to the access site. 
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Figure 2 – Predictors of all-cause mortality at follow-up 
Forest-plot showing the multivariable model for all-cause mortality, including all variables with a p-
value < 0.1 in univariate analysis. 
CI: confidence interval; HR: Hazard-ratio; STS-PROM: Society of thoracic surgeons predicted risk of 
mortality; TIA: transient ischemic attack.  
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Figure 3 - In-hospital and 30-days outcomes according to TAVI approach 
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Table 1 – Baseline characteristics of the study population according to TAVI approach 
 Transarterial 
TAVI group 
(n=87) 
Transthoracic 
TAVI group 
(n=104) 
p-
value 
Age (years) 79.3 ± 6.7 78.0 ± 9.9 0.60 
Female sex 35 (40%) 40 (39%) 0.88 
Body-mass index (kg/m²) 29.1 ± 6.7 26.4 ± 4.8 0.024 
Body-surface area (m²) 1.83 ± 0.21 1.75 ± 0.20 0.025 
NYHA class III or IV 40 (46%) 51 (49%) 0.77 
Previous acute heart failure 31 (36%) 33 (32%) 0.65 
Medical history    
Hypertension 62 (71%) 77 (74%) 0.75 
Diabetes mellitus 24 (28%) 18 (17%) 0.11 
Coronary artery disease* 42 (48%) 71 (68%) 0.008 
Previous myocardial infarction 12 (14%) 17 (16%) 0.69 
Previous coronary artery bypass grafting 15 (17%) 28 (27%) 0.12 
Previous percutaneous coronary intervention 22 (25%) 31 (30%) 0.52 
Previous balloon aortic valvuloplasty 8 (9%) 12 (12%) 0.64 
Previous surgical aortic valve replacement 7 (8%) 5 (5%) 0.39 
Other cardiac surgery 2 (2%) 3 (3%) 1.00 
Atrial fibrillation 39 (45%) 34 (33%) 0.10 
Previous permanent pacemaker 8 (9%) 13 (13%) 0.50 
Cerebrovascular disease 3 (3%) 19 (18%) 0.001 
Previous Stroke/TIA 8 (9%) 11 (11%) 0.81 
Peripheral artery disease 33 (38%) 46 (44%) 0.46 
Active cancer 3 (3%) 7 (7%) 0.35 
Previous chest radiotherapy 5 (6%) 8 (8%) 0.78 
Hostile chest - 6 (6%) 0.03 
Respiratory failure 23 (26%) 27 (26%) 1.00 
Renal failure 
  Moderate 
  Severe 
 
39 (45%) 
3 (3%) 
 
45 (43%) 
7 (7%) 
0.64 
Dialysis 2 (2%) 1 (1%) 0.59 
Severe liver disease - 1 (1%) 1.00 
Logistic EuroScore I 12.0 (7.0-21.0) 14.9 (9.7-23.0) 0.053 
Logistic EuroScore II 3.4 (1.9-5.8) 3.4 (2.4-6.9) 0.22 
STS-PROM Score 3.1 (2.2-4.8) 3.5 (2.4-4.9) 0.18 
Echocardiography    
LVEF (%) 54.2 ± 12.5 54.0 ± 13.3 0.54 
LVEF < 50% 25 (29%) 27 (26%) 0.75 
Aortic valve area (cm²) 0.74 ± 0.16 0.75 ± 0.32 0.56 
Mean aortic gradient (mmHg) 49.0 ± 15.7 47.1 ± 14.8 0.60 
Mean aortic gradient <40 mmHg 20 (23%) 26 (25%) 0.87 
Aortic regurgitation ≥ mild 21 (24%) 34 (33%) 0.20 
Mitral regurgitation ≥ mild 23 (26%) 37 (36%) 0.21 
Moderate or severe mitral stenosis 3 (3%) 3 (3%) 1.00 
Systolic pulmonary artery pressure > 60 mmHg† 10/64 (16%) 17/79 (22%) 0.40 
*Coronary artery disease defined as previous myocardial infarction, or previous percutaneous 
coronary intervention, or previous coronary artery bypass grafting, or presence of at least one 
lesion ≥ 50% on the preoperative coronary angiogram. 
†Systolic pulmonary artery pressure was measurable by echocardiography in 145 patients. 
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Table 2 – Procedural characteristics of the study population according to TAVI approach. 
 Transarterial 
TAVI group 
(n=87) 
Transthoracic 
TAVI group 
(n=104) 
p-
value 
Urgent procedure 3 (3%) 4 (4%) 1.00 
General anesthesia 79 (91%) 104 (100%) 0.002 
Approach 
  Sub-clavian 
  Carotid 
  Trans-aortic 
  Transapical 
 
73 (84%) 
14 (16%) 
- 
- 
 
- 
- 
41 (39%) 
63 (61%) 
 
Balloon-expandable valve 23 (26%) 100 (96%) <0.001 
Newer-generation valve* 70 (81%) 44 (42%) <0.001 
Valve type 
  Edwards SAPIEN 
  Edwards SAPIEN XT 
  Edwards SAPIEN 3 
  Medtronic CoreValve 
  Medtronic Evolut R 
 
1 (1%) 
- 
22 (25%) 
13 (15%) 
48 (55%) 
 
27 (26%) 
30 (29%) 
43 (41%) 
3 (3%) 
1 (1%) 
<0.001 
Valve size (mm) 
  23 
  26 
  29 
  31 
 
15 (17%) 
27 (31%) 
39 (45%) 
3 (3%) 
 
34 (33%) 
50 (48%) 
18 (17%) 
2 (2%) 
<0.001 
Number of implanted valve 
  0 
  1 
  2 
 
3 (3%) 
84 (97%) 
- 
 
- 
103 (99%) 
1 (1%) 
0.09 
Fluoroscopy time (min) 20.4 ± 7.9 13.0 ± 6.3 <0.001 
Dosimetry (Gy.cm²) 82 (55-132) 82 (55-128) 0.99 
Contrast volume (ml) 140 (110-199) 140 (108-177) 0.66 
Device success 74 (85%) 99 (95%) 0.024 
Perprocedural complications    
Perprocedural death 3 (3%) 1 (1%) 0.33 
Valve embolization or ectopic deployment 1 (1%) 2 (2%) 1.00 
Conversion to open surgery 2 (2%) 4 (4%) 0.69 
Coronary obstruction 1 (1%) - 0.46 
Tamponade 2 (2%) - 0.21 
Annulus rupture - 1 (1%) 1.00 
Left ventricular perforation 1 (1%) 1 (1%) 1.00 
* Edwards SAPIEN 3 or Medtronic Evolut R 
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Table 3 – Outcomes of the study population according to TAVI approach 
 Transarterial 
TAVI group 
(n=87) 
Transthoracic 
TAVI group 
(n=104) 
p-
value 
Cumulative in-hospital outcomes    
In-hospital composite endpoint 10 (12%) 26 (25%) 0.025 
In-hospital death 4 (5%) 8 (8%) 0.55 
Coronary obstruction 1 (1%) - 0.46 
Tamponade 2 (2%) 4 (4%) 0.69 
Myocardial infarction - 1 (1%) 1.00 
Acute heart failure 3 (3%) 10 (10%) 0.15 
Stroke / Transient ischemic attack 
 Stroke 
 Transient ischemic attack 
1 (1%) 
- 
1 (1%) 
4 (4%) 
4 (4%) 
- 
0.38 
Major or life-threatening bleeding 
  BARC 5 
  BARC 3 – total 
  BARC 3a 
  BARC 3b 
  BARC 3c 
 
- 
5 (6%) 
2 (2%) 
3 (3%) 
- 
 
- 
10 (10%) 
5 (5%) 
5 (5%) 
- 
 
- 
0.42 
0.46 
0.73 
- 
Minor bleeding – BARC definition 1 (1%) 5 (5%) 0.22 
Vascular complications 
  Major 
  Minor 
 
- 
2 (2%) 
 
- 
1 (1%) 
 
- 
0.59 
Acute kidney injury stage 2 or 3 - 8 (8%) 0.008 
Septic shock 1 (1%) 2 (2%) 1.00 
Pneumopathy 2 (2%) 8 (8%) 0.11 
Need for reintubation 1 (1%) 5 (5%) 0.22 
Delirium 3 (3%) 10 (10%) 0.15 
New-onset atrial fibrillation 4 (5%) 19 (19%) 0.003 
Permanent pacemaker implantation* 13/79 (17%) 4/91 (4%) 0.011 
Discharged at home 58/83 (69%) 43/93 (42%) 0.002 
Length of hospitalization, days† 6.0 (4.0-7.0) 7.0 (6.0-9.0) <0.001 
Echocardiographic findings at discharge    
Left ventricular ejection fraction (%) 55.8 ± 13.2 54.9 ± 12.0 0.39 
Aortic valve area (cm²) 1.95 ± 0.54 1.78 ± 0.46 0.016 
Patient-prosthesis mismatch 
  Moderate 
  Severe 
n=82 
9 (11%) 
5 (6%) 
n=95 
15 (16%) 
5 (5%) 
0.67 
Mean aortic gradient (mmHg) 11.4 ± 7.1 11.4 ± 5.3 0.55 
Paravalvular leak 
  None/trace 
  Mild 
  Moderate 
  Severe 
n=83 
58 (70%) 
21 (25%) 
3 (4%) 
1 (1%) 
n=98 
74 (76%) 
23 (24%) 
1 (1%) 
- 
0.39 
Cumulative 30-day outcomes    
30-day composite endpoint 13 (15%) 27 (26%) 0.075 
30-day death 4 (5%) 9 (9%) 0.39 
Stroke 1 (1%) 4 (4%) 0.38 
Myocardial infarction 1 (1%) 1 (1%) 1.00 
Rehospitaliazation for heart failure 7 (11%) 7 (9%) 0.78 
Major or life-threatening bleeding 
  BARC 5 
 
- 
 
- 
 
- 
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  BARC 3 – total 
  BARC 3a 
  BARC 3b 
  BARC 3c 
8 (9%) 
3 (3%) 
5 (6%) 
- 
11 (11%) 
5 (5%) 
6 (6%) 
- 
0.81 
0.73 
1.00 
- 
Major vascular complications 1 (1%) - 0.46 
Permanent pacemaker implantation* 13/79 (17%) 4/91 (4%) 0.011 
*Among patients without prior permanent pacemaker. 
† Among patients discharged alive from the hospital. 
Composite endpoint : in-hospital occurrence of any of the following : death, need for open 
surgery, tamponade, stroke, major/life-threatening bleeding, stage 2 or 3 acute kidney injury, 
coronary obstruction, major vascular complications. 
 
 
 
